Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
US5408038A · kind A · utility
40Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 8, 1992 |
| Grant date | Apr 18, 1995 |
| Priority date | — |
| Expiry date | Oct 8, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are described for determining the level of low density lipoproteins (LDL) in plasma. Native apoprotein B-100 (apo B-100) present in LDL particles is immunologically mimicked by a polypeptide of the invention. A polypeptide includes an amino acid residue sequence corresponding to a pan epitope region of the target apoprotein. A preferred polypeptide is a fusion protein that simultaneously mimics native apo B-100 and native apo A-I. Improved assay systems and methods for determining HDL and LDL levels in a body fluid sample are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.